Skip to content
Today
Sign in

InvestNot yet confirmed elsewhere1 publisher2 min readPublished

Korea's Q3 IPO class trades 25% under offer, and the selling came after the debut

Seven of eight new Seoul listings sit below their offer prices. The books cleared on day one; the damage arrived in the weeks after, which is a pricing-power problem rather than a valuation one.

The Investor · Invest desk

How we use AISend a correction

What happened

  • The Korea Exchange put the eight non-REIT, non-SPAC listings since July at an average 25% below their offer prices, on closing prices as of August 21.
  • Seven of the eight trade under offer, with Ingenia Therapeutics the single exception.
  • Both benchmarks fell less over the same stretch: the KOSPI was down 19% and the KOSDAQ down 13%.
  • The previous quarter's eight debutants had averaged a 133% first-day return against their offer prices.
  • New duplicate-listing rules require a parent to win shareholder approval under the 3% rule before separately listing a spun-off subsidiary.

Why it matters

  • constraint Pricing to the flip bid no longer works: the top of a range now has to survive several weeks of aftermarket trading with no second wave of buyers behind it.
  • exposure Allocation holders are the ones carrying the loss, and they need a 33% recovery just to reach cost before they subscribe to anything else.
  • decision Sono International and the rest of the queue now pick between accepting a cohort-wide discount on valuation or waiting on an index recovery they do not control.
  • precedent With five enumerated board duties attached to spin-off listings, group restructuring becomes a governance negotiation before it is ever a pricing exercise.

A cohort that closes its first session an average of 2.96% above offer has, in the narrow sense, been priced about right [5]. The book cleared. What happened next is the problem: measured from that average first-day close, Korea's third-quarter class has given up roughly 27% [16]. The error was not the indicative range. It was the assumption that a second layer of buyers would turn up above it.

In the second quarter that assumption paid. Three of the eight second-quarter debutants (MakinaRocks, Poled and Cosmo Robotics) closed day one at four times the offer price [8], and analysts cited by Seoul Economic Daily tie that to subscription money chasing a KOSPI that rose 68% in the quarter, with sentiment freezing once the index corrected [9]. Between the two quarters, average first-day performance moved about 130 percentage points [19].

The figure underwriters should be working from is the relative one. The third-quarter group came in six points behind the KOSPI and twelve behind the KOSDAQ, the venue where most of them listed [15]. New issues did not hold up as separate stories through the correction; they were the highest-beta way to own it. That is what a shareholder register full of allocation buyers does when the pop fails to arrive.

The individual names read the same way. HLGenomics closed its first day 31% below offer and now sits 57% below [6][4], a further 26 points after the market had already had its say on price [18]. Lemon Healthcare, which listed on the KOSDAQ on July 6 and finished its debut 6% under offer, is 48% below [6][4]. Dealicious is down 46% [4]. That shape of selling is supply meeting an absent bid, not a reaction to company news.

The rule change works on the other side of the ledger. The Financial Services Commission and the Korea Exchange published a draft on duplicate listings on July 6 and a final version on July 31 [10], and Seoul Economic Daily reports that the firming of those rules added to the wait-and-see mood in the market [20]. That thins the pipeline; it does nothing for the bid.

Goodai Global and Musinsa are being weighed as candidates [14]. Any book built on second-quarter comparables is quoting a market that only existed inside a 68% index rally [9].

What to watch

  • Whether any filed deal cuts its indicative range or withdraws in the fourth quarter, the first hard sign issuers have accepted the discount.
  • Whether fourth-quarter debuts close their first day above offer, the cheapest early read on whether allocation demand has returned.
  • Whether the first spin-off listing tested under the new parent-approval regime clears its shareholder vote.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence58
Adoption66
Hype gap−12
Incentives34
Confidence55
Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

  1. [1]

    The Korea Exchange said on August 23 that, based on closing prices as of August 21, the eight companies newly listed on the KOSPI and KOSDAQ since July, excluding REITs and SPACs, had fallen an average of 25% from their offering prices.

    ReportedSupportedSource: Korea Exchange, via Seoul Economic DailyView cited source
  2. [2]

    Over the same period the KOSPI fell 19% and the KOSDAQ fell 13%.

    ReportedSupportedView cited source
  3. [3]

    Seven of the eight new listings traded below their offering prices, with Ingenia Therapeutics the only exception.

    ReportedSupportedView cited source

Sources

1 independent publisher whose own reporting we read for this story.

  1. en.sedaily.com

    1 article · August 22, 2026

    Korean IPO Debuts Fall 25% on Average in Third Quarter

Share your take

Let Clarity write the post for you.

Signed-in readers get a short post drafted on this story in the register they choose — narrative, analytical, or a direct position — editable to the last word before it goes anywhere. The share buttons at the top of this story work without an account.

Create a free account to composeSign in

Topics and entities

Follow any of these and your For You feed starts watching them — no settings page required.

Topics

  • Korean IPO MarketFollow
  • Equity Market VolatilityFollow
  • IPO Pricing and Aftermarket PerformanceFollow
  • Capital Markets RegulationFollow

Entities

Loading related stories